To Assess the Safety, Tolerability and Efficacy of Itacitinib Immediate Release Tablets in Participants With Primary or Secondary Myelofibrosis Who Have Received Prior Ruxolitinib and/or Fedratinib Monotherapy (LIMBER-213)
Clinical trial NCT04629508 · COMPLETED
Trial details
- NCT number
- NCT04629508
- Sponsor
- Incyte Corporation
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-07-12
- Primary completion
- 2023-08-24
- Enrollment
- 4
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.